Hepatic Disease in HIV-Infected Patients
Summary
- Tenofovir DF and tenofovir AF are currently recommended for first-line HBV therapy in US (Management Guidelines)[AASLD HBV] and European guidelines (Management Guidelines)[EASL HBV]
- Tenofovir AF is approved by the FDA and EMA for treatment of chronic HBV infection[FDA TAF]
- Tenofovir AF has similar antiviral efficacy but reduced bone and kidney toxicity when compared with tenofovir DF
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content